Effects of clonidine and flesinoxan on blood pressure variability in conscious spontaneously hypertensive rats

Journal of Cardiovascular Pharmacology

Volumn 30, Issue 2, 1997, Pages 241-244

  Chaouche Teyara, Kamel ^a   Lacolley, Patrick ^a   Challande, Pascal ^b   Fournier, Berthe ^a   Laurent, Stéphane ^a   Safar, Michel ^a   Dabiré, Hubert ^a  

^a INSERM   (France)

^b NONE

Author keywords

Blood pressure variability; Clonidine; Conscious spontaneously hypertensive rats; Flesinoxan; Long term treatment; Spectral analysis

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; CLONIDINE; FLESINOXAN; IMIDAZOLINE I1 RECEPTOR; SEROTONIN 1A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG EFFECT; LONG TERM CARE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; OSMOTIC MINIPUMP; PRESSORECEPTOR; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SUBCUTANEOUS DRUG ADMINISTRATION; SYMPATHETIC TONE;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLONIDINE; HEART RATE; HYPERTENSION; INJECTIONS, SUBCUTANEOUS; MALE; PIPERAZINES; RATS; RATS, INBRED SHR; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DRUG; TIME FACTORS;

EID: 0030819276     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199708000-00014     Document Type: Article

References (28)

1. Mancia G. Blood pressure variability: mechanisms and clinical significance. J Cardiovasc Pharmacol 1990;16(suppl 6):S1-6.
2. Parati G, Ravogli A, Frattola A, et al. Blood pressure variability: clinical implications and effects of antihypertensive treatment. J Hypertens 1994;12:S35-40.
3. Parati G, Ulian L, Santucciu C, Omboni S, Mancia G. Blood pressure variability, cardiovascular risk and antihypertensive treatment. J Hypertens 1995;13:S27-34.
4. Clement DL, Debuyzere M, Duprez DD. Influence of drugs on blood pressure variability. J Hypertens 1994;12:S49-53.
5. Grichois ML, Japundzic N, Head GA, Elghozi JL. Clonidine reduces blood pressure and heart rate oscillations in the conscious rat. J Cardiovasc Pharmacol 1990;16:449-54.
6. Elghozi JL, Laude D, Janvier F. Clonidine reduces blood pressure and heart rate oscillations in hypertensive patients. J Cardiovasc Pharmacol 1991;17:935-40.
7. Janssen BJA, Tyssen CM, Struijker-Boudier HAJ. Modification of circadian blood pressure and heart rate variability by five different antihypertensive agents in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1991;17:494-503.
8. Tulen JHM, Smeets FML, Intveld AJM, Vansteenis HG, Vandewetering BJM, Moleman P. Cardiovascular variability after clonidine challenge - assessment of dose-dependent temporal effects by means of spectral analysis. J Cardiovasc Pharmacol 1993;22: 112-9.
9. Snyder DW, Nathan MA, Reis DJ. Chronic lability of arterial pressure produced by destruction of the catecholamine innervation of the nucleus tractus solitarii in the rat. Circ Res 1978;43:662-71.
10. 2 catecholaminergic neurons in rat brain stem. Circ Res 1980;46:842-53.
11. Buchholtz RA, Nathan MA. Chronic lability of arterial blood pressure produced by electrolytic lesions of the nucleus tractus solitarii in the rat. Circ Res 1984;54:227-38.
12. Vanzwieten PA. From alpha and beta to I-1: an overview of sympathetic receptors involved in blood pressure control targets for drug treatment. J Cardiovasc Pharmacol 1996;27:55-10.
13. Wouters W, Hartog J, Bevan P. Flesinoxan. Cardiovasc Drug Rev 1988;6:71-83.
14. McCall RB, Clement ME. Role of serotonin (1A) and serotonin (2) receptors in the central regulation of the cardiovascular system. Pharmacol Rev 1994;46:231-43.
15. Eerdmans PHA, Struyker-Boudier HAJ, de Mey JGR. Contractile reactivity of isolated resistance arteries after 4 weeks of treatment with rilmenidine, clonidine or hydralazine in spontaneously hypertensive rats. J Hypertens 1991;9(suppl 6):S348-9.
16. Naruse T, Ishii R, Tagawa T. Absence of tolerance to hypotensive effects of clonidine in spontaneously hypertensive rats. Jpn J Pharmacol 1995;67:407-10.
17. Lacolley P, Glaser E, Challande P, et al. Structural changes and in situ aortic pressure-diameter relationship in long-term chemical-sympathectomized rats. Am J Physiol 1995;38:H407-16.
18. Cerutti C, Gustin MP, Paultre CZ, et al. Autonomie nervous system and cardiovascular variability in rats: a spectral analysis approach. Am J Physiol 1991;261:H1292-9.
19. Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res 1980;47:1-9.
20. Murphy CA, Sloan RP, Myers MM. Pharmacologic responses and spectral analyses of spontaneous fluctuations in heart rate and blood pressure in SHR rats. J Auton Nerv Syst 1991;36:237-50.
21. Alper RH, Jacob HJ, Brody MJ. Central and peripheral mechanisms of arterial pressure lability following baroreceptor denervation. Can J Physiol Pharmacol 1987;65:1615-8.
22. Cerutti C, Barres C, Paultre C. Baroreflex modulation of blood pressure and heart rate variabilities in rats: assessment by spectral analysis. Am J Physiol 1994;266:H1993-2000.
23. Jacob HJ, Ramanathan A, Pan SG, Brody MJ, Myers GA. Spectral analysis of arterial pressure lability in rats with sinoaortic deafferentation. Am J Physiol 1995;38:R1481-8.
24. Head GA. Baroreflexes and cardiovascular regulation in hypertension. J Cardiovasc Pharmacol 1995;26:S7-16.
25. Emsberger P, Damon TH, Graff LM, Schafer SG, Christen MO. Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites. J Pharmacol Exp Ther 1993; 264:172-82.
26. Chan CKS, Sannajust F, Head GA. Role of imidazoline receptors in the cardiovascular actions of moxonidine, rilmenidine and clonidine in conscious rabbits. J Pharmacol Exp Ther 1996;276:411-20.
27. Kleine P, Meissner E, Bruchhausen VV, Bruckner S. Effects of clonidine and nifedipine on left ventricular hypertrophy and muscle mass in hypertensive patients. J Cardiovasc Pharmacol 1987; 10:8180-6.
28. Timio M, Venanzi S, Gentili S, Ronconi M, Del Re G, Del Vita M. Reversal of left ventricular hypertrophy after one-year treatment with clonidine: relationship between echocardiographic findings, blood pressure, and urinary catecholamines. J Cardiovasc Pharmacol 1987;10:S142-6.